Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
4.29 ^USD	-5.09%		-16.54%	-31.63%

May. 15	Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	MT
May. 15	T2 Biosystems Shares Rise After CRG Servicing Ups Stake	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	May. 15	MT
Top Midday Gainers	May. 15	MT
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	May. 07	CI
T2 Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M	May. 06	MT
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024	May. 06	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Middle East Distributor	May. 06	CI
T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	Feb. 12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	Feb. 12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	Jan. 18	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	Jan. 03	CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference	23-10-24	CI
T2 Biosystems Submits 510(k) to Add Detection of Acinetobacter Baumannii to List of Pathogens Covered by T2Bacteria Panel	23-10-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Highlights

Filters